

**No. 31026/05/2017-Pricing
Government of India
Ministry of Chemicals & Fertilizers
Department of Pharmaceuticals**

Shastri Bhawan, New Delhi
Dated, the 21.02.2017

To

**M/s India Medtronic Pvt Ltd,
1241, Solitaire Corporate Park, Building No. 12,
Ghatkopar Andheri Link Road,
Andheri (E) Mumbai – 400093.**

**Subject:- Ensuring compliance of the pricing capping of the Coronary Stents
alongwith maintaining its uninterrupted supply - regarding.**

Sir,

I am directed to refer on the above mentioned subject and to say that some reports regarding shortage of Coronary Stents in the market/hospitals has now come to the notice of the Department.

2. After due deliberations on the current situation and alternatives available with the government to resume normal supply of the coronary stents, it has been decided to invoke the powers of Section 3 (i) of DPCO, 2013 which provides as under:-

“The Government may,-(i) with a view to achieve adequate availability and to regulate the distribution of drugs, in case of emergency or in circumstances of urgency or in case of non-commercial use in public interest, direct any manufacturer of any active pharmaceutical ingredient or bulk drug or formulation to increase the production and to sell such active pharmaceutical ingredient or bulk drug to such other manufacturer(s) of formulations and to direct formulators to sell the formulations to institutions, hospitals or any agency as the case may be.”

3. The Companies manufacturing coronary stents in India are directed:-

- (i) to maintain production/import/supply of the coronary stents;
- (ii) to submit a weekly report on coronary stents produced and distributed. They will also submit a weekly production plan for the next week to NPPA and DCGI;

4. NPPA and DCGI are also empowered to extend these directions to any other producers of Coronary stents in India during this three months period.

5. This order will be valid for next six months and NPPA and DCGI will recommend withdrawal or extension as the case may be, two weeks before the expiry of the period.

6. This issues with the approval of Secretary (Pharmaceuticals).

Yours faithfully,

**(Barnali Khastgir)
Under Secretary to the Govt. of India
Phone: 23383392
Email: barn.khast@nic.in**